Tinea Capitis
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
NovartisBASEL, Switzerland
2 programsTerbinafine hydrochloridePHASE_32 trials
Terbinafine hydrochloridePHASE_31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
NovartisTerbinafine hydrochloride
NovartisTerbinafine hydrochloride
Clinical Trials (3)
Total enrollment: 1,470 patients across 3 trials
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
Start: Jul 2004Est. completion: Apr 2006720 patients
Phase 3Completed
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
Start: Jun 2004720 patients
Phase 3Completed
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
30 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.